Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives.
Forbion currently manages over €1 bn across ten closed-end funds, including its $360m Forbion IV Fund, launched in 2018, for which Forbion is actively looking for new exciting opportunities. Forbion has a team of thirteen investment professionals across two offices in The Netherlands and Germany.
Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 50 companies. Forbion has already had considerable success with this strategy via its first three funds, with the EUR 183 million Forbion III already delivering 4 exits including the sale of Rigontec to MSD and the highly successful IPO of Replimune on NASDAQ in July 2018.
Forbion helps companies to bridge research and development through the team’s expertise in drug development and company building. Forbion is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect health and well-being of patients. Its investors include the EIF, notably through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI) and AMUF facilities, and the KFW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion also operates a joint venture with BioGeneration Ventures, who manages three separate seed and early stage funds focused on Benelux and Germany